AOD-9604 in Avrig — Fat Loss Peptide Research Guide
AOD-9604 research guide for Avrig. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers searching for AOD-9604 in Avrig rapidly learn that local retail options are all but absent from local stores. What this means for Avrig researchers is that geography is secondary to your ability to verify analytical documentation — and those evaluation tools are within reach of all serious researchers. The key verification criteria for AOD-9604 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. This guide walks Avrig researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
AOD-9604 Mechanisms Explained
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Avrig studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
AOD-9604 Purchasing Guide
Before evaluating any specific vendor, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from bacterial cell wall components can trigger dangerous inflammatory cascades even at very low concentrations. For Avrig researchers evaluating new suppliers: a test quantity before committing to research volumes before placing larger orders is what experienced peptide researchers consistently do. Store lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order AOD-9604 — ships to Avrig
COA-verified · International tracking · Research grade
AOD-9604 operates outside approved pharmaceutical regulation — researchers should understand that the known safety profile is based on academic studies rather than pharmaceutical approval data. Reconstitute AOD-9604 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. The research literature on AOD-9604 should be studied thoroughly before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
